Tailor Bio
Drug Discovery
- Website
- https://tailor.bio/
- Membership category
- Emerging Y2
Office G16, 47-51 Norfolk Street, Cambridge, CB1 2LD, United Kingdom
Tailor Bio at a glance
A pan-cancer precision medicine company with a novel approach to discover novel therapeutics and diagnostics using Chromosomal Instability biomarkers.
About Tailor Bio
Chromosomal Instability (CIN) is an enabling hallmark of cancer with genomes exhibiting CIN showing accumulation of large-scale losses, gains, and rearrangements of DNA. These rearrangements can be caused by a variety of factors and molecular mechanisms. Different causes of CIN result in different patterns of DNA copy number changes and these patterns have been identified as CIN signatures. For example, the most common CIN signature, CX1, is caused by chromosome mis-segregation via defective mitosis and/or telomere dysfunction.
This underlying molecular mechanism results in copy number changes that affect entire arms of chromosomes, or entire chromosomes themselves. CIN signatures characterise the multiple forms of instability present in individual cancer samples and can be related to clinical phenotypes.
CIN is a fundamental hallmark of cancer, but until now it has not been able to understand its complexity. Tailor’s co-founders have developed a comprehensive framework to decode this deadly phenomenon and enable new opportunities for precision medicine. Our CIN signatures unlock new methods of drug target discovery and improved patient stratification for targeted therapies. By measuring the activity of these patterns, or signatures in a patient’s tumour, we can determine the causes of CIN, which we can then use to inform therapy selection.
